Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Bactiguard, Audiocast with teleconference, Q1'24

By Inderes4/25/2024, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Thomas Venkatesh
00:00 - 02:25

Thank you, Operator, and welcome to the presentation of Bactiguard's Q1 2024 report. This is Thomas Venkatesh speaking. The former CEO. I want to share a brief reflection before I hand over to our new CEO, Christine Lind, and Patrick Bach, our CFO. They'll go through the quarterly presentation and will be available for questions on the report afterwards. So, two weeks ago on Friday, I formally handed over the CEO role to Christine, concluding an 11-month tenure leading Bactiguard. It's been a very intense and disruptive period with a strategic shift to focus on the license. Business was the most central change, and going from being a production-based business to a specialist and knowledge organization. When I assumed the role last summer. Little did I know what was about to come. We now have set the right strategy and inspiring vision to become the global standard of care in preventing device-related infections. Under the leadership of Christine and her team. I'm confident that Bactiguard will become an instrumental company in the fight to protect patients from dangerous, uncoated medical device products that today cause half of all hospital-acquired infections. I would like to express a big and warm thank you to the entire Bactiguard team. We have all chipped in a very direct way despite the tough decisions and actions. You're such a high-caliber team once again. Thank you. And on a personal note, being operationally responsible for Bactiguard has been very tough. We are separated from a lot of good and qualified people, which has not been fun whatsoever. With that said, though, it's been necessary when implementing a new vision and focused licensed strategy. I would do my utmost to support Christine and the team in my upcoming capacity as chairman of the board. Obviously subject to the upcoming shareholders' meeting electing me. I'm humble, but I'm upbeat about our future. With that, I'm handing over the show to Christine.

Christopher
02:27 - 12:32

Thank you, Thomas. It is great to be here. And thank you all for dialing in to what is my very first Bactiguard quarterly report, delivered on my second Thursday as the CEO. As I stated in the CEO comments, I am looking forward to working with our sophisticated Board of Directors, including with Thomas as the incoming chairman as well as Kristen King in his new role as Senior Advisor. It is so valuable to have this full support. For those of you to whom I am new. My quick background. I have spent more than 25 years in and around the life sciences sector, including in CEO and business development and strategy positions, as well as in investment banking at Merrill Lynch in New York, advising biotech and pharma companies. I am an American, hence my very American accent. I have lived in Sweden since 2015 and yes, I do speak Swedish. Turning more importantly to the Q1 2024 report. The key message that we want to relay is that the strategic transformation has been concluded, and I would like to provide more details on that. If you have followed Bactiguard for a while, you will recognize this slide. We first showed it in connection with the announcement of the sharpened License Focus strategy in Q3, and I would like to go through it one last time to showcase what we have achieved in terms of the transformation and restructuring of the company. Let us review these achievements by the articulated focus area, starting with licensing. First, we have strengthened the organization both in terms of capabilities and ways of working. We are now working in a project-based manner, with the partner relationship in focus, with the aim to continue to strengthen long-term collaborations through teamwork and accountability for results so that Bactiguard is recognized as a true partner, rather than being seen solely as a solution provider or a contract manufacturer. Second, we have already enhanced the relationships with our current partners, in particular with BD (Becton, Dickinson and Company), but also with Zimmer Biomet. I will come back to this a little bit later in the presentation. Third, we are intensely engaged in dialogue with new potential partners. However, given the new way we will report revenues, we will not provide more information on these new partners until we enter exclusivity partnerships. In other words, we will announce once we are closer to starting to generate revenues, which we believe is more relevant from a financial perspective. Later in the presentation, Patrick will elaborate further on the framework for the reporting of our various partnership stages. The next focus area is R&D and our coating technology. We have further institutionalized the entire R&D organization, processes, and structure. We have kicked off the Billy Södervall Academy, although this is still in very early days, so I will not formally tick that off yet. Lastly, work is well underway on the production and laboratory facility in Madrid, and we hope to have it up and running sometime during Q2. Going forward, all coating, materials, production, and development activities will take place in Sweden in one of our two facilities in Tullinge or Märsta. Turning to the BIP portfolio. Importantly, we licensed out the full list to BD and the handover process of these additional markets is making great progress. We're in the final stages of winding down sales of our own medical devices for the CDSCO and ETS. We are in conversations with potential partners, but it is still too early to report on, and it is important to note that we expect these activities to have very limited impact in 2024. To summarize the financial impact of the strategic transformation, we are on track to deliver cost savings of more than 25 million SEK on a yearly basis. Separate from the licensing strategy. I would also like to emphasize our focus on growing the wound management business, consisting of both the wound healing offering of Hydrocyn aqua, and a wide range of surgical sutures, including specialist sutures for cardiovascular and ocular operations. In its totality, this sharpened strategy is how we will be able to deliver on our vision to be the premier partner to leading medtech companies, joining forces to redefine infection prevention and improve health worldwide. This is the last time we will address this slide. Q1 will be the last quarter characterized by the transformation, but we expect continued activities stemming from the transformation during the remainder of 2024 as we fully transition to the new strategy. So let's dig into our business. Becton, Dickinson, or BD, is one of the global market leaders within the urology therapeutic area. BD is our longest, strongest, and closest partnership. In fact, we have been partners with BD since 1995 and over the years, more than 230 million Bactiguard coated Foley catheters have been sold. No adverse events associated with the coating technology have been reported, and the product has generated more than 3.5 billion USD in additional sales for BD. With BD, we share common values and a commitment to always put patients first and have the ambition to make the world a healthier place. As mentioned already in the Q4 presentation, the estimated global market value of Foley catheters sold around the world is in excess of 1.5 billion USD annually, and is estimated to grow by around 5% every year. In the category of strengthening existing partnerships. BD is a perfect example. Late December last year, we signed an interim agreement granting BD an exclusive global license, excluding China, for Bactiguard coated Foley catheters, and an expanded long-term license agreement is expected to be signed during the first half of 2024. So what have we accomplished in Q1? Bactiguard obtained MDR regulatory approval in Europe for the coated silicone Foley catheters. This marks an important milestone as it will support and accelerate the go-to-market strategy in Europe. It is also a good example of Bactiguard's capabilities as a specialist and knowledge organization, where our ability to navigate the rather complex European regulatory landscape has provided great value to our partnership. We also attended BD's Global Sales and Marketing Summit in the US, where our BD project leader held a presentation on how our coating technology is differentiated and benefits their urology and critical care portfolios. This is really important to repeat, as the strength of our offering to our licensed partners is that the coating technology differentiates their medical devices in the market. So please keep that in mind. Some 50 BD sales and marketing leaders from various markets listened in and engaged in a lively Q&A. A little fun fact in the photo to the right is Micah Brinkley. This is BD's star salesman of Bactiguard coated catheters in the US. Clearly we have a lot of ambassadors within BD, and they are also a crucial part of the future potential for Bactiguard. In connection with the license agreement announced in December 2024 for additional markets for Bactiguard coated Foley catheters. The transition is ongoing and making great progress. The transfer will continue throughout 2024 and during this period, either we or BD will ensure that the market demand is met with the new agreement with BD. We believe our historically stable partnership is now strengthened and is a growing one. I'll start with a short recap of our partnership with Zimmer Biomet. Zimmer Biomet is a global leader in the orthopedic therapeutic area, and our partnership involves two categories. The first, signed in 2019, relates to Zimmer Biomet orthopedic trauma implants, for which Bactiguard received CE marking for the coated version in 2021. Today, this trauma nail system is called ZNN Bactiguard. In 2022, the partnership with Zimmer Biomet was expanded to cover multiple product segments, such as implants for various types of reconstructive surgeries. I would also like to mention that in 2023, Zimmer Biomet had an overarching strategic theme called Let's Talk About Infections, used at conferences and in various conversations. Bactiguard attended many of these, highlighting how our technology could prevent infections, a critical topic within orthopedic procedures. Looking at how the trauma collaboration specifically has developed in Q1, the demand for ZNN Bactiguard continues to increase following the launch across European markets in 2023. The uptake is, however, at a slower pace than we originally anticipated, but the interest and recognition among clinicians is strong, and the need for safe and effective infection prevention strategies is getting more and more attention. The next important event is the launch of ZNN Bactiguard in Japan, which is still planned at the end of Q2. Here again, we understand it will take some time before sales should be expected to ramp up. It is important to bear in mind that successful launch and sales of new technologies and products within our industry takes time and persistence. Together with Zimmer Biomet, we are continuously moving forward. Interestingly, once the ZNN Bactiguard is launched in Japan, Zimmer Biomet will offer Bactiguard coated products in markets representing around 50% of their trauma sales. We are confident that infection prevention is a very important issue to healthcare systems. Bactiguard coated products have strong clinical evidence and thus we know that our technology adds value. Coated products have strong clinical evidence and thus we know that our technology adds value. Now over to you, Patrick, to dig deeper into the financial results.

Thomas Venkatesh
12:35 - 12:36

Thank you, Christine.

Patrick Bach
12:36 - 20:38

I am very happy to present our Q1 financial results, which indeed highlight the end of our strategic transformation and are in line with our expectations. Turning to the Q1 figures. We delivered total revenues of 58.8 million SEK. EBITDA of -1.5 million SEK. A net loss of -9.9 million SEK. And cash flow from operating activities of -19.1 million SEK for the quarter. Total revenue for the first quarter amounted to 58.8 million SEK, as mentioned, a decrease of 2.4 million SEK, corresponding to 4%. Adjusted for currency effects of 3 million SEK, revenue decreased by 9%. EBITDA for the first quarter amounted to 1.5 million SEK, an increase of 5 million SEK. And the EBITDA margin was -2.6%. Net loss for the first quarter was a 9.9 million SEK loss versus 22 million SEK last year. Cash flow from operations for the quarter amounted to -19.1 million SEK. Note that this is mainly due to a change in accounts receivables of -16 million SEK, which are driven by outstanding amounts not yet due in the quarter with our long-standing partners. As for key events in the quarter. First, as we announced in our year-end report, we have agreed with Dentsply Sirona not to pursue the application development project further. Secondly, Hydrocyn aqua received approval to start commercialization in India. And thirdly, obtained MDR-approval for our coated silicone Foley catheters, which will support Bactiguard's go-to-market strategy in Europe. As we are happy to report revenues this quarter in a new detailed split. I would like to recap our business model, which we introduced in connection with our Q3 report and detailed in our year-end and annual report. Our partnership phase on the left-hand side, and the partnership phase on the right-hand side, follow a well-defined roadmap and show in a more relevant and transparent way how we evolve our revenue. Revenue-generating partnerships. Our revenues are generated across these three segments. Application development partners, exclusivity partners, and license partners. A development partner participates in a project where we test coding technology through various medical devices, services, and materials. The Tactical Coating Development team works in close collaboration with the partner here. Some application development projects were not materialized, and this is a natural part of a business. An exclusivity partner gets an exclusive right to apply our coating technology to a certain medical device, but has no products in the market yet, for instance, due to pending regulatory approvals. Sigma BioMed and their broader orthopedics portfolio is an example of an exclusivity partner. A licensed partner has the right to market and sell medical devices with the basic R&D coding technology in a certain region or globally. Most of our revenues are generated through partnerships at this stage. BD and Zimmer Biomet and their trauma implant, ZNN Bactiguard are examples of these licensed partner revenue streams. Please note, all partnerships will not follow all these three stages, and an agreement with a partner can generate revenues from the different phases and streams simultaneously. Now turning to our actual revenue split for Q1. Total license revenue amounted to SEK 35.1 million. Decrease of 4 million, corresponding to 11%, adjusted for currency effects. Revenues from BD amounted to 28 million, a decrease of 8 million, corresponding to a 23% decrease, adjusted for currency. Worth noting is that Q1 2024 was another record year for BD, who was building up stock, which was subsequently downward adjusted during Q2 2024. Revenues from Sigma BioMed amounted to 3.2 million, an increase of 1.4 million. Revenues from the wound management portfolio amounted to 12.7 million, an increase of 1.6 million. Revenues from our BIP portfolio amounted to 6 million SEK. This is an increase of 1 million. And the growth is primarily due to the portfolio's end-of-life sales. In connection with the discontinuation we have announced in connection with the transformation. Other revenues amounted to 4.9 million, a decrease of. Point six million, currency effects in this quarter amounted to 2.8 million Swedish krona. So, total revenue for the first quarter amounted to SEK 58.8 million, a decrease of SEK 2.4 million, adjusted for total currency effects of SEK 3 million. Our revenues decreased by 8.8%. Now turning to our operating costs and cash flow for Q1. Since Q3, we have focused on our strategic transformation and, as communicated, we are on track to deliver cost savings exceeding 25 million SEK on a yearly basis following the transformation. Costs for raw materials and consumables for the first quarter amounted to 11.5 million SEK. A decrease of 2.7 million, corresponding to 19%. Other external costs amounted to 18.8 million, a decrease of 4 million, corresponding to 19%. Personnel costs amounted to 29 million, an increase of 2.9, corresponding to 9%. Other operating expenses related to currency exchange losses amounted to -0.7 million. In total, our operating expenses, or OPEX, amounted to 48.8 million, which is a decrease of 4.8 million, corresponding to 9%. Cash flow from our operating activities for the quarter amounted to -19.1 million. This is mainly due to changes in our current receivables of 16 million, which is driven by outstanding amounts not yet due in the quarter with our longstanding partners. Cash flow from investing activities amounted to 6.2 million. And this is mainly attributable to investments in our new sites and in digital systems. Cash flow from financing activities for the quarter amounted to -6.3 million, which is mainly due to amortization of loans of 3.8 million. In total, cash flow for the quarter amounted to -31.6 million, and total cash and cash equivalents at the end of the period amounted to 95.8 million. With that, I'm happy to hand over to you, Christine.

Christopher
20:39 - 22:17

Thank you, Patrick. So, time to wrap up. You have seen this slide many times before, but it is truly crucial when putting our infection prevention technology into perspective, both from a financial and societal impact perspective. On the left-hand side, the demand for more effective and safe healthcare solutions is clear, driven by economic and demographic developments as well as the unfortunate increase in political unrest, conflicts, wars, and natural disasters. There are clear unmet medical needs with the global societal challenges, including healthcare-associated infections and antimicrobial resistance being as pressing as ever. Notably, prevention strategies are, according to the World Health Organization, one of the most important factors to solving these issues. Turning to the right-hand side. While I'm fully aware of the challenges Bactiguard has had in the past. Our top priority ahead is to truly seize the 80 billion US dollar opportunity presented within the strategic therapeutic areas that are key for our infection prevention technology and in wound management. With the licensing focus strategy, both revenues and margins are expected to increase for Bactiguard as we expand the use of our infection prevention technology globally through partnerships. We are set to scale up in a cost-effective manner and create profitable and sustainable growth for the future. And with that, we are now ready for any questions you may have, either on the line or in the chat. Operator.

Mathias Waddesdon
22:18 - 22:40

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Christopher Lederberg from Carnegie. Please go ahead.

Unknown
22:43 - 23:15

Thank you and good morning. I have two questions. First, if you could give any update on the new extended collaboration with BD on a global scale. Secondly, if I look at what you report now as license partner revenue, 32.4, if I add up BD sales and the CMA sales that you wrote about in the text, that's 41.2 million. So, I just wonder what the rest is on that line. Thank you.

Christopher
23:16 - 24:22

Thank you, Christopher. I'll take your first question on the BD collaboration, and we'll ask Patrick to respond to the license revenue question, if that is okay. On the BD collaboration, it is a good relationship, of course. Even closer today than it was in the past. I think it is beneficial that we are moving from having been a competitor to them in other markets to being a partner, which is good for the relationship, even in the already existing markets in the US, Japan, Europe, and our other new markets. We do need to remember that the approvals are Bactiguard's. The product is Bactiguard; the sales material, and the sales force were Bactiguard's. And we are in a transition period where it is ongoing. But it does take time. We are also very happy to have had the MDR approval in Europe, as we do believe that this will help BD ramp up. So, all in all, the collaboration, I think, is going very well to date. And of course, the partnership feels stronger than ever. And on the license revenues.

Unknown
24:23 - 24:40

Could I ask a follow-up to the BD sales you had in the quarter? If I remember the 6 million or so, that will go to zero more or less, and instead, you will get a higher royalty from BD in the coming quarters.

Patrick Bach
24:42 - 25:32

This is Patrick. Just to answer your question regarding the sales. The total sales is what we have announced earlier that we are discontinuing. We have announced that this will impact our revenues by up to 25 million. Whereas we said at the same time, we're reducing costs by exceeding 25 million. During this year, we will see BD sales until we have fully transitioned all the markets to BD. So depending on that transition, we will see in the coming quarters as well, perhaps some portfolio sales. But our expectation is that this will obviously continue to decrease.

Unknown
25:33 - 25:47

Okay, but when do you expect some meaningful impact on the BD line from royalties? In new markets, so outside Japan and the US.

Patrick Bach
25:50 - 26:05

As we have communicated, our licensing of our BIP portfolio, including the Foley catheters to BD, but also the other products, will have a limited effect in 2024.

Unknown
26:07 - 26:08

Okay.

Unknown
26:10 - 26:15

And, the other question on the license partner revenue line.

Unknown
26:17 - 26:17

Yeah, yeah.

Patrick Bach
26:17 - 26:27

So your question was, in addition to BD and similar. Which drove the revenue in the license portion of the revenue stream.

Unknown
26:30 - 26:31

Yeah, exactly.

Unknown
26:31 - 26:37

If I add those two, that's lower than the 32.4 million reported on that line.

Unknown
26:38 - 26:39

Yeah, yeah.

Patrick Bach
26:39 - 26:51

In that pocket, we have license revenue from all our license partners. And as we have previously communicated, we do also have a license partnership with Wal-Mart for alcoholic beverages in China.

Unknown
26:53 - 27:00

Okay, that makes sense. But could I just ask you. Is all the Zimmer revenue booked in that line?

Patrick Bach
27:02 - 27:25

Our total revenues for the quarter were 3.2 million. In general, and also for this quarter. The Zimmer revenues do split into both the license partner revenue stream, the exclusivity partner revenue stream, and also to some extent, the application development partner revenue stream.

Unknown
27:27 - 27:38

Okay, so we have no idea how much of Zimmer is through underlying royalties and how much is just. Non-recurring.

Patrick Bach
27:39 - 27:50

We have reported the total amount for Zimmer. Yes. We have not specified in the report the detailed split on those three categories for Zimmer, but.

Unknown
27:51 - 28:08

Could you give some color on that because I guess, you know, ramping up those Zimmer revenues will be extremely important for you to have any chance of reaching the financial guidance or the medium term guidance. I think it's a very important metric.

Patrick Bach
28:10 - 28:59

Yes. As Christine mentioned, Zimmer is rolling out in Europe, as we speak and also expected to launch in Japan in late Q2. So the revenues that we recognized for Zimmer include both the in-market sale royalty. It includes also minimum royalties, and it includes exclusivity fees in terms of annual exclusivity fees and milestone fees. The nature of these revenue streams do differ over the year. And they differ also with respect to the timing of when we recognize these. And that's why you will see some fluctuations over the year in the Zimmer revenues.

Christopher
29:00 - 29:27

And Christopher, from a qualitative standpoint, we can repeat that as Patrick said that the European launch is ongoing. Interest from clinicians is very high. And what we're hearing is that once a clinician is converted to Bactiguard, they don't go back. Conversion of the rest of the market, of course, does take time. But we are quite confident in the enthusiasm around the bacterial products in the market.

Unknown
29:28 - 29:28

That they have.

Unknown
29:28 - 29:34

Still, they have only launched one of the many trauma products with the coating in Europe.

Christopher
29:35 - 29:38

Yes, it is the ZNN Bactiguard that is the launch product.

Unknown
29:39 - 29:39

Okay.

Unknown
29:39 - 29:40

Thank you.

Christopher
29:43 - 29:44

Thank you, Christopher.

Mathias Waddesdon
29:49 - 29:55

The next question comes from Mathias Waddesdon from SEB. Please go ahead.

Dan Spicer
29:57 - 29:58

Hi. Thank you. Can you hear me?

Christopher
29:59 - 30:00

Yes, we hear you.

Dan Spicer
30:01 - 30:27

Good. Uh, thanks for taking my questions. First one on Dan Spicer. On not to pursue the application development project further. It was announced in Q4, of course, but happened in Q1. My question is, if you remain as upbeat in this segment for the infection prevention technology, and if you have already today sort of negotiations with further players ongoing. Uh, that's my first one.

Christopher
30:28 - 31:14

Thank you, Matthias. It's a great question. Uh, and yes, we are as confident in the coating technology in the dental arena as we were before. Uh, we do have, uh, how will I say, multiple discussions ongoing. Um, and I guess, uh, I liken it a little bit to synchronized swimming, uh, which is to say that there'll be lots of effort here. Uh, but the market will only get to see the part above the water. Uh, so when we actually announce the, uh, collaboration and exclusivity agreements with our partners, whereas, uh, all of the vigorous swimming under the surface will not be announced. Uh, but rest assured, it is ongoing. And we do believe quite a lot in our technology in this area.

Dan Spicer
31:17 - 31:51

Thanks for that. And then I think wound management products, uh, developed well in 2023 and saw some growth here in Q1. I mean, in this segment, what's in your view is, uh, sort of reasonable growth rates ahead in, in, let's say, coming years. And then if there are any trigger points with sort of a new market launch or, you know, let's say some further products coming online or anything to support the boost in sales growth for that sort of segment coming year. That's my next one.

Patrick Bach
31:53 - 33:08

Thank you, Matthias. Um, Patrick here. Um, I appreciate the question about the wound management portfolio. Uh, wound management includes both our Hydrocyn aqua product and also our sutures business. Wound management is a business that we expect to grow and to grow profitably. Uh, so we do expect growth rates from the wound management going forward as well. In Q1, we saw almost $12.7 million in sales and 14% growth. Uh, and as I mentioned, we do expect continued growth and profitability from the wound management business going forward. As we stated, as an event in the quarter, in India in early February, we did receive approval to start commercialization. Um, so obviously we do expect sales from India this year. Uh, and from a base of nothing. So, we do expect some growth there. Uh, but overall for the wound management business, yes. This is growing now. And we do expect continued growth and profitability from that business.

Dan Spicer
33:11 - 33:40

Good. And then in terms of the royalty revenues, here in Q1 and also Q4, is that representing normalized figures for this agreement, in your view? And then it has, of course, been volatile in recent years and also during Covid for understandable reasons. You know, is it fair to assume, let's say, a more stable development ahead, or will we always have those kind of stocking effects when it comes to that agreement? That's my last one.

Unknown
33:42 - 33:42

Yeah.

Patrick Bach
33:42 - 34:35

Thank you, Matthias, appreciate the question. Uh, indeed. We have seen fluctuations in the past year, which hit us, indeed, in Q2 and Q3 of last year, as we communicated in Q4 of last year, we saw BD levels being back on track. Um, and the volumes and the activity we have with BD in Q4, but also continued here in Q1, shows us that we expect that this will continue to be on a stable and solid level. Uh, we don't expect any major fluctuations. Um, but of course, we are subject to BD sales and to their production. Um, but overall, we are very confident about the potential and the collaboration with BD going forward.

Dan Spicer
34:37 - 34:57

Good. Maybe, maybe one more question for me as well, to follow up on the earlier question about dip sales, how that will be phased out, would you say, you know, is it fair to assume it's about zero when you exit here, or, you know, zero in Q4? Or how should we see it?

Unknown
35:00 - 35:01

Um.

Patrick Bach
35:01 - 36:09

As we have communicated, our strategic intent was to license the values to BD, which we have done for Europe and globally, excluding China. At the same time, we have been the producer, and we have stock levels and we have customers that are demanding the product, as Christine touched upon, we are in the transition phase. And while we are handing over the license to BD, we also want to make sure that our existing demand is being met. And of course, that our inventories rundown. So this is a process that we carefully handle, and you can expect that we will sell obviously less products. But depending on this handover, we will see sales in quarters to come. We cannot say exactly when we will see the last bit of sale. But this is the development that we expect.

Dan Spicer
36:10 - 36:22

Okay, good. But let's say you are not producing anything more in this, so it's only the inventories that will be sold.

Patrick Bach
36:23 - 36:51

We have as part of the transformation, discontinued the portfolio, which includes also shutting down our manufacturing in Malaysia, in Chennai. That is planned for this year. So we will discontinue production. We will not produce more. So to say, after 2024, hence we will deplete inventories and, in that, production. Yes.

Dan Spicer
36:54 - 36:56

Okay. Thanks for the answers.

Unknown
36:58 - 36:58

Thank you.

Mathias Waddesdon
37:04 - 37:36

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Christopher
37:38 - 37:47

Thank you. Operator. And thank you, everyone, for listening in today to our Q1 2024 call. We look forward to seeing you again in the.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…